Biosimilars News
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Drug development consultancy Certara has published a report on the Inflation Reduction Act’s (IRA) impact on oncology biosimilar uptake. 29 August 2024
Privately-held German drugmaker Boehringer Ingelheim has inked a deal with GoodRx (Nasdaq: GDRX), in a bid to boost US penetration of its biosimilar to Humira (adalimumab). 18 July 2024
Exclusive
Company Spotlight
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Most Read
13 May 2024
In Brief
Korean company Samsung Biologics has signed a production agreement with an unidentified large US pharma corporation worth more than $1.06 billion. 3 July 2024
Mergers and Acquisitions
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
25 September 2023
24 August 2023
21 August 2023
16 June 2022
30 March 2022
Editor's Pick
Boardroom
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Swiss pharma giant Novartis’s board of directors announced today the appointment of Gilbert Ghostine as chairman-designate of the new board of Sandoz, its biosimilars and generics business. 20 February 2023
The American business of South Korea's Celltrion Healthcare has appointed Thomas Nusbickel as chief commercial officer. 7 February 2023
India’s largest biotech firm Biocon today announced that Shreehas Tambe, currently deputy chief executive of its Biocon Biologics (BBL) subsidiary, has been appointed as managing director of the company, with effect from December 5, 2022. Mr Tambe will lead BBL in realizing its goal of being a global biosimilars leader. 5 December 2022
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze